What happened
Inbiogen updated its previously filed separate results for FY2025: revenue of US$4.19M (−10.6% year on year), an operating loss of US$2.89M and a net loss of US$945K (from a profit a year earlier).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$4.19M |
|---|---|
| Revenue vs a year earlier | −10.6% |
| Operating profit | −US$2.89M |
| Net income | −US$945K |
| Period | FY2025 (separate) |
| Filed | 2026-03-16, [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260316800407 → open original filing |
Versions of this filing
- 2026-02-12Original
- 2026-03-16Amendment 1 (this page)
Source: DART. Information only, not investment advice.